Volume 19, Number 10—October 2013
Human Infection with Eurasian Avian-like Influenza A(H1N1) Virus, China
To the Editor: We report a human infection with avian-like swine A(H1N1) influenza virus first identified through a surveillance system for influenza like illness (ILI) in mainland China. An influenza virus, isolated from a patient with ILI, was originally subtyped as influenza A(H1N1)pdm09 virus with a hemagglutination inhibition (HI) test, but it was identified as a Eurasian avian-like influenza A(H1N1) virus (EA-H1N1) by full genome sequencing on January 30, 2013. The virus was named A/Hebei-Yuhua/SWL1250/2012 (H1N1v) (HB/1250/12), according to the definition of the World Health Organization (1).
The case-patient was a 3-year-old boy who had symptoms of fever and sore throat; his highest body temperature was 38°C on December 9, 2012. He was brought for medical treatment to an influenza sentinel hospital in the city of Shijiazhuang in Hebei Province, China, on December 12. He recovered within a week without hospitalization and oseltamivir treatment. A throat swab specimen was collected and sent to the local Chinese Center for Disease Control and Prevention for virus isolation and characterization, according to the Guidelines of the Chinese National Influenza Surveillance Network. A retrospective investigation was conducted to identify the potential infection source and any other possible cases. The case-patient was previously healthy and had no history of close contact with animals (live or dead wild birds, poultry, and swine) within 2 weeks before the onset of symptoms, nor a history of travel. He lived with his sister and parents; all other family members did not develop influenza-like symptoms during the period of the investigation.
Sporadic human infections with swine influenza virus had been reported previously (2,3). Another case-patient, infected by EA-H1N1 influenza virus A/Jiangsu/1/2011(JS11) in early 2011, was reported (4,5). The genome sequences of the viruses isolated from the 2 case-patients showed high homology; the similarity of the polymerase basic protein 2 was 99.1%; of polymerase basic protein 1, 99.3%; of polymerase acidic protein, 98.9%; of hemagglutinin (HA), 99.1%; nucleocapsid protein, 99.1%; neuraminidase protein, 99.2%; matrix protein, 99.6% and of nonstructural protein, 99.2% (Global Initiative on Sharing Avian Influenza Data, GISAID, accession no.EPI301156–63 for JS11 and EPI438417–25 for HB/1250/12). The HB/1250/12 virus has the amino acids D (at site 190) and E (at site 225) within the HA protein, which are reported to be critical for enhancement of the HA affinity in binding to α-2,6–linked sialosides (6). The virus was resistant to amantadine and rimantadine with S31N (Ser→Asn) mutation in M2 gene, but was predicted to be susceptible to the neuraminidase inhibitor drugs oseltamivir and zanamivir on the basis of the neuraminidase gene.
HI test with ferret anti-serum against A(H1N1)pdm09 (CA09), seasonal H3N2(Vic11,BR10/07 and Perth09), classical swine subtype H1N1(NJ76), and the seasonal influenza subtype H1N1 viruses (BR59/07, SI06) showed that the HB/1250/12 virus is antigenically indistinguishable from NJ76 and CA09, but different from subtype H3N2 viruses (Vic11, BR10/07, and Perth09) and seasonal subtype H1N1 viruses(BR59/07, SI06) (Technical Appendix Table [PDF - 92 KB - 1 page]). These findings were consistent with results reported previously (7–9).
To estimate the susceptibility of human population to this virus, and to investigate whether seasonal trivalent inactivated influenza vaccine (TIV) could provide cross-protection, we collected serum samples from children, adults, and elderly adults, before and after 2012–2013 TIV vaccination, and the antibody against HB/1250/12 virus was tested by HI assay. The seroprotection antibody was defined as HI titers >40. Before vaccination, 28% of children (3–5 years) and 6.7% of adults (18–59 years) had HI titers >40, but elderly adults (>60 years) did not. Samples from 56% of children, 56.7% of adults, and 26.7% of elderly adults had HI titers >40 after TIV vaccination; however, a 4-fold antibody rise developed in <30% in any age group (Table). These results indicated that a proportion of cross-protective antibody against EA-H1N1 exists in children and adults, whereas elderly adults are the most susceptible to EA-H1N1 infection with no cross-protective antibody, the vaccination with TIV could not substantially improve the level of cross-reactive EA-H1N1 antibodies.
Antisera from hyperimmune sheep are usually used for influenza virus typing and subtyping, the CA09 sheep antisera reacted well with the HB/1250/12 virus (Technical Appendix Table [PDF - 92 KB - 1 page]). This is the reason why the local Chinese Center for Disease Control and Prevention originally subtyped HB/1250/12 as A(H1N1)pdm09 virus. Such avian-like H1N1 virus could be missed with regular HI test. In addition, a large proportion of swine influenza infection cases are mild and even asymptomatic (2); thus, the human infections with swine influenza virus may have been underestimated in China.
This is the first human case of EA-H1N1 infection identified through the national ILI surveillance network in China, indicating that the influenza surveillance network not only plays a critical role in monitoring the seasonal influenza circulation and the vaccine virus selection, but also is useful for early detection of novel influenza viruses with pandemic potential. This study also highlighted the value of, and urgent demand for, a cost-effective sequencing platform on routine influenza surveillance for pandemic preparedness.
This work was partly supported by National Basic Research Program of China (973 program, no. 2011CB504704) and the China Mega-Project for Infectious Disease (no. 2012ZX10004215).
- World Health Organization. Standardization of terminology for the variant A(H3N2) virus recently infecting humans [cited 2013 Mar 12]. http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/en/indexhtml.
- Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis. 2007;44:1084–8 .
- Adiego Sancho B, Omenaca Teres M, Martinez Cuenca S, Rodrigo Val P, Sanchez Villanueva P, Casas I, Human case of swine influenza A (H1N1), Aragon, Spain, November 2008. Euro Surveill. 2009;14:••• .
- Qi X, Cui L, Jiao Y, Pan Y, Li X, Zu R, Antigenic and genetic characterization of a European avian-like H1N1 swine influenza virus from a boy in China in 2011. Arch Virol. 2013;158:••• .
- Yang H, Qiao C, Tang X, Chen Y, Xin X, Chen H. Human infection from svian-like influenza A (H1N1) viruses in pigs, China. Emerg Infect Dis. 2012;18:1144–6.
- Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol. 2000;74:8502–12.
- Vijaykrishna D, Smith GJ, Pybus OG, Zhu H, Bhatt S, Poon LL, Long-term evolution and transmission dynamics of swine influenza A virus. Nature. 2011;473:519–22.
- Vijaykrishna D, Poon LL, Zhu HC, Ma SK, Li OT, Cheung CL, Reassortment of pandemic H1N1/2009 influenza A virus in swine. Science. 2010;328:1529.
- Zhu H, Zhou B, Fan X, Lam TT, Wang J, Chen A, Novel reassortment of Eurasian Avian-like and pandemic/2009 influenza viruses in swine: infectious potential to humans. J Virol. 2011;85:10432–9.
- Table. Cross-reactive antibody response against avian-like influenza A(H1N1) virus in pediatric and adult recipients of seasonal trivalent inactivated influenza vaccines, China, 2013†
- Technical Appendix. . Table showing cross-reactive antibody response against avian-like influenza A(H1N1) virus in pediatric and adult recipients of seasonal trivalent inactivated influenza vaccines, China, 2013 92 KB
Suggested citation for this article: Wang D-Y, Qi S-X,1 Li X-Y, Guo J-F, Tan M-J, Han G-Y, et al. Human infection with Eurasian avian-like influenza A(H1N1) virus, China. Emerg Infect Dis [Internet]. 2013 Oct [date cited]. http://dx.doi.org/10.3201/eid1910.130420
1These authors contributed equally to this article.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Address for correspondence: Yuelong Shu, National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, 102206, People’s Republic of China
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: September 17, 2013
- Page last updated: September 17, 2013
- Page last reviewed: September 17, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)